Benzene Ring Nonionically Bonded Patents (Class 514/567)
  • ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH
    Publication number: 20130310325
    Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
    Type: Application
    Filed: September 23, 2011
    Publication date: November 21, 2013
    Inventors: Geert W. Schmid-Schonbein, Yung-Tsai Lee, Jeng Wei, Marisol Chang, Pedro Cabrales
  • LIQUID PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A POSTERIOR EYE DISEASE
    Publication number: 20130303473
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 14, 2013
    Applicant: NOVALIQ GmbH
    Inventor: Clive G. Wilson
  • SHEET AND LIQUID COMBINATION SYSTEMS FOR DERMAL DRUG DELIVERY
    Publication number: 20130304002
    Abstract: A dermal drug delivery system is provided which comprises at least two components, for example, a sheet of a solid and flexible material, and a vehicle liquid comprising a solvent and optionally other ingredients. A drug, which can be unstable in said solvent but needs the solvent for being delivered into the skin, can be impregnated in the sheet. Other ingredients, such as agents for fastening the drug on the sheet can also be impregnated in the sheet. These two components may be stored separately and joined either shortly before or at the time of application. To use the system, the vehicle liquid may be applied either on the target skin area or on the sheet, and the sheet may then be applied on the target skin area so that the vehicle liquid is positioned between the sheet and the skin and brought into contact with the ingredients impregnated in the sheet.
    Type: Application
    Filed: November 8, 2011
    Publication date: November 14, 2013
    Inventor: Jie Zhang
  • OCULAR BIODEGRADABLE DRUG IMPLANT AND METHOD OF ITS USE
    Publication number: 20130302420
    Abstract: A biodegradable drug implant includes a PLG matrix and a non-steroid anti inflammation drug, for example diclofenac sodium. The implant is inserted into the eye in the anterior chamber, for example in the ciliary sulcus, following eye surgery. A method for treating and or preventing inflammation of the eye following eye surgery includes placing the implant in the anterior portion of the eye.
    Type: Application
    Filed: May 14, 2012
    Publication date: November 14, 2013
    Inventors: Barry L. Bowyer, James P. Gills
  • Acetaminophen/ibuprofen combinations and method for their use
    Patent number: 8580856
    Abstract: A pharmaceutical dosage form is provided comprising a non-steroidal anti-inflammatory agent and acetaminophen, and methods for their use. In one embodiment, the dosage form is comprised of ibuprofen and acetaminophen as the sole pharmaceutically effective agents, wherein the ibuprofen and acetaminophen are in a weight ratio of about 12 parts:about 88 parts.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: November 12, 2013
    Assignee: NcNeil-PPC, Inc.
    Inventors: Jim Swann, Peter Cummins
  • Acetaminophen / ibuprofen combinations and method for their use
    Patent number: 8580855
    Abstract: A pharmaceutical dosage form is provided comprising a non-steroidal anti-inflammatory agent and acetaminophen, and methods for their use. In one embodiment, the dosage form is comprised of ibuprofen and acetaminophen as the sole pharmaceutically effective agents, wherein the ibuprofen and acetaminophen are in a weight ratio of about 12 parts:about 88 parts.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: November 12, 2013
    Assignee: McNeil-PPC, Inc.
    Inventors: Jim Swann, Peter Cummins
  • Compositions and methods for treating neurodegenerating diseases
    Patent number: 8580776
    Abstract: This invention provides agents, compositions, pharmaceutical compositions and methods for treating or slowing the progression of a neurodegenerating disease, such as Alzheimer's disease and a demyelinating disease.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: November 12, 2013
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Douglas L. Feinstein, Maria Vittoria Simonini, Sergey Kalinin, Paul E. Polak
  • POLYMORPHS OF BROMFENAC SODIUM AND METHODS FOR PREPARING BROMFENAC SODIUM POLYMORPHS
    Publication number: 20130289120
    Abstract: Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 31, 2013
    Inventors: Saroop Singh Matharu, Gurijala Venu Reddy, James J. Mencel, Xiaoyong Sun
  • 3,5,3'-Triiodothyronine Sulfate As Thyromimetic Agent And Pharmaceutical Formulations Thereof
    Publication number: 20130281536
    Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
    Type: Application
    Filed: June 13, 2013
    Publication date: October 24, 2013
    Inventors: Aldo PINCHERA, Livio CAVALIERI, Federico MAISANO, Giovanni RIVOLTA, Ferruccio SANTINI, Fulvia VELLA
  • AQUEOUS LIQUID BROMFENAC COMPOSITION HAVING PRESERVATIVE EFFICACY
    Publication number: 20130281537
    Abstract: An aqueous liquid bromfenac composition containing (a) bromfenac or a salt thereof and (b) benzalkonium chloride, characterized by that the composition has preservative efficacy and that the concentration of (b) benzalkonium chloride is higher than 0.0005% and lower than 0.005%.
    Type: Application
    Filed: January 18, 2012
    Publication date: October 24, 2013
    Inventors: Shuichi Nishihata, Wakiko Asayama, Suzuka Iemoto
  • Diclofenac topical formulation
    Patent number: 8563613
    Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: October 22, 2013
    Assignee: Nuvo Research Inc.
    Inventors: Ed Kisak, Jagat Singh
  • DRUG DELIVERY COATING AND DEVICES
    Publication number: 20130273137
    Abstract: In various embodiments, the present invention provides certain systems comprising a multi-layer decomposable film coating composition on a substrate, where the coating composition includes one or more releasable agents in at least one of its layers, and decomposes layer-by-layer to release such agent(s) over time. In some embodiments, an intra-ocular lens (IOL) system comprising an IOL coated with a multi-layer decomposable film coating composition is disclosed.
    Type: Application
    Filed: May 3, 2011
    Publication date: October 17, 2013
    Applicants: MASSACHUSETTS EYE & EAR INFIRMARY, Massachusetts Institute of Technology
    Inventors: Kenneth J. Mandell, Paula T. Hammond, Renee C. Fuller, Joseph F. Rizzo, III, Anita Shukla
  • Methods of treatment utilizing topical emulsion-gel composition comprising diclofenac sodium
    Patent number: 8557870
    Abstract: The invention relates to methods for treating burns or inflammation utilizing beneficial pharmaceutical compositions comprising diclofenac sodium salt in unusually low amounts. The compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: October 15, 2013
    Assignee: Novartis Consumer Health S.A.
    Inventor: Michel Steiger
  • Method for prevention of alzheimer's disease
    Publication number: 20130267601
    Abstract: A method for prevention of Alzheimer's Disease (AD) is presented. The principal cause of AD is a deficiency at the cellular level of the human brain, of the effects of the active form of thyroid hormone, tri-iodothyronine (T3). Lifelong T3 replacement, beginning in early to mid life and, in some cases later, overcomes these blocks to T3 production and actions and prevents AD in a majority of the sub-types of AD.
    Type: Application
    Filed: April 9, 2012
    Publication date: October 10, 2013
    Inventor: Joseph Michael Abramowitz
  • MOISTURE RESISTANT CONTAINER SYSTEMS FOR RAPIDLY BIOAVAILABLE DOSAGE FORMS
    Publication number: 20130267602
    Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.
    Type: Application
    Filed: February 18, 2013
    Publication date: October 10, 2013
    Applicant: APR Applied Pharma Research, S.A.
    Inventors: Giorgio Reiner, Alberto Reiner
  • Use of combination preparations comprising antifungal agents
    Patent number: 8552042
    Abstract: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: October 8, 2013
    Inventors: Christian Noe, Marion Noe
  • Methods of Treating Autism
    Publication number: 20130261186
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. The humans can be administered the GABA(B) agonist in a single dose or multiple doses.
    Type: Application
    Filed: June 7, 2013
    Publication date: October 3, 2013
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF
    Publication number: 20130259932
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Application
    Filed: May 22, 2013
    Publication date: October 3, 2013
    Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
  • Percutaneous absorption type plaster
    Patent number: 8545873
    Abstract: A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2, wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is ? times by mass to 4 times by mass as that of the rosin-based resin.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: October 1, 2013
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
  • Methods for enhancing hematopoietic progenitor cell engraftment
    Patent number: 8546382
    Abstract: Described herein are methods for improving engraftment of hematopoietic cells in an individual following hematopoietic progenitor cell transplantation (e.g., via bone marrow or cord blood transplantation). Methods for increasing hematopoietic progenitor cell proliferation in individuals with bone marrow aplasia are also described. The methods involve administering an agent that inhibits adipogenesis, adipocyte growth, adipocyte differentiation and/or adipocyte proliferation.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: October 1, 2013
    Assignee: Children's Medical Center Corporation
    Inventors: Olaia Naveiras, George Daley, Pamela L. Wenzel
  • METHOD OF DROXIDOPA SYNTHESIS
    Publication number: 20130253061
    Abstract: The present application relates to a novel method of preparing L-threo-dihydroxyphenylserine (droxidopa). Specifically, the application is directed to a method of preparing droxidopa via a deprotection step that is an alternative to deprotection steps that have been previously disclosed. The new deprotection strategy is advantageous in that it avoids the need to use hydrogenolysis or hydrazine.
    Type: Application
    Filed: March 8, 2013
    Publication date: September 26, 2013
    Applicant: CHELSEA THERAPEUTICS, INC.
    Inventors: Harish K. Pimplaskar, Shashikant Vithal Kadam, Vooradi Mallesh, Pramod Mangaldas Kawale
  • ORAMUCOSAL PHARMACEUTICAL DOSAGE FORM
    Publication number: 20130252916
    Abstract: This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound. The invention also extends to a method of manufacturing an oramucosal pharmaceutical dosage form in the form of a wafer which involves freeze drying or lyophilisation.
    Type: Application
    Filed: January 8, 2013
    Publication date: September 26, 2013
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventor: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
  • Topical pharmaceutical formulation
    Patent number: 8541470
    Abstract: A composition for topical application of an NSAID comprises a solution or suspension of the NSAID in a carrier system comprising a polyhydric alcohol, a glycol ether and an ester of A higher fatty acid, the carrier system being present as a single phase at ambient temperatures. The NSAID may be diclofenac as diclofenac acid. The polyhydric alcohol may be a glycol such as isopropylene glycol and the glycol ether may be a diethylene glycol ether such as diethylene glycol monoethyl ether.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: September 24, 2013
    Assignee: Futura Medical Developments Limited
    Inventor: Adrian Francis Davis
  • Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators
    Patent number: 8541397
    Abstract: The present invention relates to novel alkyne and alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: September 24, 2013
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita Bhat, Evelyn Corpuz, Ken Chow, Wenkui K. Fang, Wha-Bin Im
  • TOPICAL COMPOSITIONS
    Publication number: 20130243707
    Abstract: Topical compositions are disclosed that are useful for delivering a therapeutic level of an NSAID to a target within a subject having a local inflammatory disorder. A composition of the present invention comprises a Drug and a solvent system, wherein the solvent system comprises at least two solvent alcohols and wherein the solvent system is present in an amount sufficient to solubilize the Drug, the solvent system is a low alkanol system, and the composition is a single phase composition. Exemplary solvent systems are those for which one of the at least two solvent alcohols is polyethylene glycol, glycerin, butylene glycol, diproylene glycol, propylene glycol, ethanol, isopropanol, or a derivative thereof. Optionally the local inflammatory disorder is pseudofolliculitis barbae, dermatitis, psoriasis, wounds, or sunburn.
    Type: Application
    Filed: March 28, 2013
    Publication date: September 19, 2013
    Inventors: Monique Renata GREEN, Kenton FEDDE
  • THREO-DOPS CONTROLLED RELEASE FORMULATION
    Publication number: 20130243875
    Abstract: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.
    Type: Application
    Filed: May 10, 2013
    Publication date: September 19, 2013
    Applicant: CHELSEA THERAPEUTICS, INC.
    Inventors: Stephen Peroutka, James Swarbrick
  • NOVEL COMPOUND AND MEDICAL USE THEREOF
    Publication number: 20130245074
    Abstract: Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa.
    Type: Application
    Filed: December 1, 2011
    Publication date: September 19, 2013
    Applicant: ONO PHARMACEUTICALS CO., LTD.
    Inventors: Masaya Kokubo, Koji Yano
  • DICLOFENAC FORMULATIONS AND METHODS OF USE
    Publication number: 20130245122
    Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
    Type: Application
    Filed: January 16, 2013
    Publication date: September 19, 2013
    Applicant: APR Applied Pharma Research S.A.
    Inventors: Giorgio Reiner, Alberto Reiner, Andreas Meyer
  • AGONISTS OF GPR40
    Publication number: 20130237571
    Abstract: The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are therefore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.
    Type: Application
    Filed: July 20, 2011
    Publication date: September 12, 2013
    Applicant: Conexios Life Sciences PVT. LTD.
    Inventors: Jagannath Madanahalli Ranganath Rao, Nagarajan Arumugam, Mohd Mudabbir Ansari, Chandrasekhas Gudla, Shanmugam Pachiyappan, Manivannan Ramalingam, Jenson George, George Fernanda Arul, Kenchegowda Bommegowda, Y, Sathesh Kumar Angupillai, Ramamoorthy Kottamalai, Pradeep Jidugu, Shivanageshwara Rao, D
  • FORMULATION AND MANUFACTURE OF PHARMACEUTICALS BY IMPREGNATION ONTO POROUS CARRIERS
    Publication number: 20130236511
    Abstract: The present invention provides methods for impregnating a porous carrier with an active pharmaceutical ingredient (“AP”), the methods comprising steps: a) dissolving at least one API in a solvent to form an API solution; b) contacting a porous carrier with the at least one API of step (a) in a contactor to form an API impregnated porous carrier; and c) drying the at least one API impregnated porous carrier.
    Type: Application
    Filed: August 19, 2011
    Publication date: September 12, 2013
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Fernando J. Muzzio, Benjamin J. Glasser, Plamen I. Grigorov
  • Polymer formulations for delivery of bioactive materials
    Patent number: 8529922
    Abstract: PLGA, PLA and PGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units. The polymers are particularly useful for drug delivery.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: September 10, 2013
    Assignee: Landec Corporation
    Inventors: David Taft, Stelios Tzannis, Wei-Guo Dai, Sandra Ottensmann, Steven Bitler, Qiang Zheng, Adam Bell
  • High concentration baclofen preparations
    Patent number: 8529916
    Abstract: Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: September 10, 2013
    Assignee: Board of Regents The University of Texas System
    Inventors: Lawrence A. Trissel, Yanping Zhang
  • ROS-Activated Compounds as Selective Anti-Cancer Therapeutics
    Publication number: 20130230542
    Abstract: Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 5, 2013
    Applicants: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Edward J. Merino, James C. Mulloy, Guorui Li, Tiffany Bell-Horwath
  • Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia
    Patent number: 8524758
    Abstract: Ophthalmic compositions for the treatment of presbyopia, including combinations of parasympathomimetics and non-steroidal anti-inflammatories.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: September 3, 2013
    Inventor: Jorge Luis Benozzi
  • GEODATE DELIVERY VEHICLES
    Publication number: 20130224284
    Abstract: The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for later addition of cargo moieties are also contemplated.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 29, 2013
    Inventors: Raphael J. Mannino, Sara L. Krause-Elsmore, Susan Gould-Fogerite, David Delmarre, Ruying Lu
  • GASTRIC RETAINED GABAPENTIN DOSAGE FORM
    Publication number: 20130224289
    Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 29, 2013
    Applicant: Depomed, Inc.
    Inventor: Depomed, Inc.
  • Therapeutic Compounds
    Publication number: 20130225517
    Abstract: The invention provides compounds of formula I: or salts thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I and therapeutic methods for treating cancer.
    Type: Application
    Filed: February 22, 2013
    Publication date: August 29, 2013
    Applicant: University of Iowa Research Foundation
    Inventor: University of Iowa Research Foundation
  • Methods and compositions for the treatment of irritable bowel syndrome
    Patent number: 8518995
    Abstract: A method for a prevention and/or treatment of irritable bowel syndrome or amelioration of a symptom thereof in a subject, comprises administering to said subject an effective amount of a compound of formula I:
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: August 27, 2013
    Assignee: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Yuichi Iwaki, Kale Ruby
  • Aqueous intraocular penetration-promoting eye drop
    Patent number: 8518996
    Abstract: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 27, 2013
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Tomoko Fujimoto
  • Method and Device for assistance in delivery of medication, and Formulas
    Publication number: 20130217773
    Abstract: This invention is designed for the convenient and reliable delivery of predetermined doses of topical therapeutic medications applied to the skin. The importance of this method of application is that it allows reducing the amount of a therapeutic agent used in one session or reducing amount of sessions per day by eliminating the application of medications to a treating surface by hand. The emphasis is on making therapeutic agents available for self-administration, especially for partially disabled people with conditions such as arthritis and/or visual impairments who would not be able to use these medications without assistance.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 22, 2013
    Inventor: Mikhail Levitin
  • Compounds and Compositions for the Treatment of Cancer
    Publication number: 20130217645
    Abstract: New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil.
    Type: Application
    Filed: October 26, 2011
    Publication date: August 22, 2013
    Applicant: PROMETIC BIOSCIENCES INC.
    Inventors: Lyne Gagnon, Brigitte Grouix, Lilianne Geerts, Pierre Laurin, Christopher Penney, Boulos Zacharie
  • PHENOXY DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS
    Publication number: 20130217651
    Abstract: The present invention relates to novel phenoxy derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: February 20, 2013
    Publication date: August 22, 2013
    Applicant: ALLERGAN, INC.
    Inventor: ALLERGAN, INC.
  • METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY
    Publication number: 20130209488
    Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
    Type: Application
    Filed: August 5, 2011
    Publication date: August 15, 2013
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC
    Inventors: Vikas P. Sukhatme, Jian-Guo Ren
  • NOVEL FORMULATION OF DICLOFENAC
    Publication number: 20130209569
    Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
    Type: Application
    Filed: January 25, 2013
    Publication date: August 15, 2013
    Applicant: iCeutica, Inc.
    Inventor: iCeutica, Inc.
  • SUSTAINED RELEASE FORMULATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG
    Publication number: 20130209547
    Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
    Type: Application
    Filed: March 6, 2013
    Publication date: August 15, 2013
    Applicant: PACIRA PHARMACEUTICALS INC.
    Inventor: PACIRA PHARMACEUTICALS INC
  • MODULATION OF AMINO ACID METABOLISM IN THE HYPOTHALAMUS
    Publication number: 20130209433
    Abstract: Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyper-VLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal.
    Type: Application
    Filed: December 12, 2012
    Publication date: August 15, 2013
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Albert Einstein College of Medicine of Yeshiva University
  • SUSTAINED RELEASE FORMULATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG
    Publication number: 20130209548
    Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
    Type: Application
    Filed: March 6, 2013
    Publication date: August 15, 2013
    Applicant: PACIRA PHARMACEUTICALS, INC.
    Inventor: PACIRA PHARMACEUTICALS, INC.
  • Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis
    Publication number: 20130202580
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.
    Type: Application
    Filed: February 14, 2013
    Publication date: August 8, 2013
    Applicant: AmDerma Pharmaceuticals, LLC
    Inventor: AmDerma Pharmaceuticals, LLC
  • Preparation for Improving Solubility of Poorly Soluble Drug
    Publication number: 20130203723
    Abstract: The present invention relates to solubility improving preparation for enhancing the oral absorption of a poorly soluble drug, which is comprising (A) and (B); (A) a granulated substance which comprises (i) a poorly soluble drug having an acidic group in the molecule, (ii) an alkaline agent, (iii) a surfactant, and this granulated substance dose not substantially contain a disintegrator, (B) a disintegrator existing only in the external of the granulated substance.
    Type: Application
    Filed: September 29, 2011
    Publication date: August 8, 2013
    Inventors: Satoshi Sakuma, Hiroshi Ueda, Akira Mashimo, Hiroshi Murazato
  • SUBSTITUTED 8-ALKOXY-2-AMINOTETRALIN DERIVATIVES, AND USE THEREOF
    Publication number: 20130203751
    Abstract: The present application relates to novel substituted 8-alkoxy-2-aminotetraline derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.
    Type: Application
    Filed: May 9, 2011
    Publication date: August 8, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Walter Hübsch, Michael Hahn, Alexandros Vakalopoulos, Volkhart Min-Jian Li, Frank Wunder, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Friederike Stoll, Niels Lindner